Risk-Reducing Mastectomy Cost-Effective With Breast Cancer Risk ≥35 Percent
By Elana Gotkine HealthDay Reporter
MONDAY, July 28, 2025 -- Undergoing risk-reducing mastectomy (RRM) seems to be cost-effective for women aged 30 to 55 years with a lifetime breast cancer (BC) risk of 35 percent or higher, according to a study published online July 24 in JAMA Oncology.
Xia Wei, Ph.D., from the London School of Hygiene & Tropical Medicine, and colleagues defined lifetime BC risk thresholds for RRM in an economic evaluation using a decision-analytic Markov model. The cost-effectiveness of RRM was compared to BC screening and medical prevention (tamoxifen or anastrozole) in a simulated cohort.
In the simulated cohort of 100,000 30-year-old women, the researchers found that RRM became cost-effective at a 34 percent lifetime BC risk using the £30,000 per quality-adjusted life-year (QALY) gained and compared with the U.K. willingness-to-pay (WTP) threshold. The identified lifetime BC risk thresholds for RRM to be cost-effective were 31, 29, 29, 32, 36, and 42 percent among women aged 35, 40, 45, 50, 55, and 60 years, respectively, using the £30,000 per QALY WTP threshold. For women aged 30 to 55 years with a lifetime BC risk of at least 35 percent, undergoing RRM was deemed cost-effective, with more than 50 percent of simulations cost-effective in a probabilistic sensitivity analysis. For women with a lifetime BC risk of 35 percent or higher, offering RRM could potentially prevent approximately 6,538 BCs or about 11 percent of the 58,756 BC cases occurring annually among women in the United Kingdom.
"The results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers, and could potentially prevent 6,500 BC cases annually," the authors write. "Future studies evaluating the acceptability, uptake, and long-term impact of RRM among these women are needed."
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
Perioperative Counseling Reduces Opioid Use After ACL Reconstruction Surgery
TUESDAY, July 29, 2025 -- Opioid-limiting pain management education and counseling reduce opioid consumption with no increase in postoperative pain among patients undergoing...
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
FRIDAY, July 18, 2025 -- Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.